MedTrace Logo

Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.

NCT02662894 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2021-02-24

No results posted yet for this study

Summary

Noninferiority trial to assess efficacy of fixed-dose combination of valsartan + rosuvastatin versus their isolated components in treatment of hypertension and dyslipidemia.

Conditions

Interventions

DRUG

Valsartan 160mg + Rosuvastatin 20mg

1 tablet, oral, a day

DRUG

Valsartan 320mg + Rosuvastatin 20mg

1 tablet, oral, a day

DRUG

Diovan® 160mg + Crestor® 20mg

Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.

DRUG

Diovan® 320mg + Crestor® 20mg

Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2020-09-30
Completion
2020-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02662894 on ClinicalTrials.gov